69 related articles for article (PubMed ID: 9300678)
1. Administration of IL-12 induces a CD3+ CD4- CD8- B220+ lymphoid population capable of eliciting cytolysis against Fas-positive tumor cells.
Tsutsui T; Mu J; Ogawa M; Yu WG; Suda T; Nagaga S; Saji F; Murata Y; Fujiwara H; Hamaoka T
J Immunol; 1997 Sep; 159(6):2599-605. PubMed ID: 9300678
[TBL] [Abstract][Full Text] [Related]
2. Multiple roles of interferon-gamma in the mediation of interleukin 12-induced tumor regression.
Ogawa M; Yu WG; Umehara K; Iwasaki M; Wijesuriya R; Tsujimura T; Kubo T; Fujiwara H; Hamaoka T
Cancer Res; 1998 Jun; 58(11):2426-32. PubMed ID: 9622084
[TBL] [Abstract][Full Text] [Related]
3. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
Hashimoto W; Osaki T; Okamura H; Robbins PD; Kurimoto M; Nagata S; Lotze MT; Tahara H
J Immunol; 1999 Jul; 163(2):583-9. PubMed ID: 10395644
[TBL] [Abstract][Full Text] [Related]
4. A pivotal role for CC chemokine receptor 5 in T-cell migration to tumor sites induced by interleukin 12 treatment in tumor-bearing mice.
Uekusa Y; Yu WG; Mukai T; Gao P; Yamaguchi N; Murai M; Matsushima K; Obika S; Imanishi T; Higashibata Y; Nomura S; Kitamura Y; Fujiwara H; Hamaoka T
Cancer Res; 2002 Jul; 62(13):3751-8. PubMed ID: 12097285
[TBL] [Abstract][Full Text] [Related]
5. A critical role for a peritumoral stromal reaction in the induction of T-cell migration responsible for interleukin-12-induced tumor regression.
Ogawa M; Umehara K; Yu WG; Uekusa Y; Nakajima C; Tsujimura T; Kubo T; Fujiwara H; Hamaoka T
Cancer Res; 1999 Apr; 59(7):1531-8. PubMed ID: 10197625
[TBL] [Abstract][Full Text] [Related]
6. IL-2 induces Fas ligand/Fas (CD95L/CD95) cytotoxicity in CD8+ and CD4+ T lymphocyte clones.
Esser MT; Dinglasan RD; Krishnamurthy B; Gullo CA; Graham MB; Braciale VL
J Immunol; 1997 Jun; 158(12):5612-8. PubMed ID: 9190908
[TBL] [Abstract][Full Text] [Related]
7. Enhanced induction of very late antigen 4/lymphocyte function-associated antigen 1-dependent T-cell migration to tumor sites following administration of interleukin 12.
Ogawa M; Tsutsui T; Zou JP; Mu J; Wijesuriya R; Yu WG; Herrmann S; Kubo T; Fujiwara H; Hamaoka T
Cancer Res; 1997 Jun; 57(11):2216-22. PubMed ID: 9187124
[TBL] [Abstract][Full Text] [Related]
8. Tumor-bearing mice exhibit a progressive increase in tumor antigen-presenting cell function and a reciprocal decrease in tumor antigen-responsive CD4+ T cell activity.
Zou JP; Shimizu J; Ikegame K; Yamamoto N; Ono S; Fujiwara H; Hamaoka T
J Immunol; 1992 Jan; 148(2):648-55. PubMed ID: 1345922
[TBL] [Abstract][Full Text] [Related]
9. Anti-Her-2/neu-IL-2 or heregulin-IL-2 fusions proteins redirect non-tumor specific CTL to the tumor site for tumor eradication.
Lustgarten J
Cancer Immunol Immunother; 2003 Dec; 52(12):751-60. PubMed ID: 12827309
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms underlying IFN-gamma-mediated tumor growth inhibition induced during tumor immunotherapy with rIL-12.
Yu WG; Yamamoto N; Takenaka H; Mu J; Tai XG; Zou JP; Ogawa M; Tsutsui T; Wijesuriya R; Yoshida R; Herrmann S; Fujiwara H; Hamaoka T
Int Immunol; 1996 Jun; 8(6):855-65. PubMed ID: 8671675
[TBL] [Abstract][Full Text] [Related]
11. LPS-stimulated SJL macrophages produce IL-12 and IL-18 that inhibit IgE production in vitro by induction of IFN-gamma production from CD3intIL-2R beta+ T cells.
Yoshimoto T; Nagai N; Ohkusu K; Ueda H; Okamura H; Nakanishi K
J Immunol; 1998 Aug; 161(3):1483-92. PubMed ID: 9686615
[TBL] [Abstract][Full Text] [Related]
12. IL-12 plasmid-enhanced DNA vaccination against carcinoembryonic antigen (CEA) studied in immune-gene knockout mice.
Song K; Chang Y; Prud'homme GJ
Gene Ther; 2000 Sep; 7(18):1527-35. PubMed ID: 11021590
[TBL] [Abstract][Full Text] [Related]
13. Fas/Fas ligand interaction regulates cytotoxicity of CD4+ T cells against staphylococcal enterotoxin B-pulsed endothelial cells.
Urayama S; Kawakami A; Matsuoka N; Tsuboi M; Nakashima T; Kawabe Y; Koji T; Eguchi K
Biochem Biophys Res Commun; 1997 Oct; 239(3):782-8. PubMed ID: 9367846
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production.
Shustov A; Nguyen P; Finkelman F; Elkon KB; Via CS
J Immunol; 1998 Sep; 161(6):2848-55. PubMed ID: 9743345
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms of immune-mediated lysis of murine renal cancer: differential contributions of perforin-dependent versus Fas-mediated pathways in lysis by NK and T cells.
Sayers TJ; Brooks AD; Lee JK; Fenton RG; Komschlies KL; Wigginton JM; Winkler-Pickett R; Wiltrout RH
J Immunol; 1998 Oct; 161(8):3957-65. PubMed ID: 9780164
[TBL] [Abstract][Full Text] [Related]
16. Ameliorating effect of anti-Fas ligand MAb on wasting disease in murine model of chronic colitis.
Dan N; Kanai T; Totsuka T; Iiyama R; Yamazaki M; Sawada T; Miyata T; Yagita H; Okumura K; Watanabe M
Am J Physiol Gastrointest Liver Physiol; 2003 Oct; 285(4):G754-60. PubMed ID: 12969829
[TBL] [Abstract][Full Text] [Related]
17. Signal requirement for induction of MHC-unrestricted antitumor cytotoxicity of human T cell CD4+/CD8+ subpopulations.
Zhu HG; Klein-Franke A; Anderer FA
Anticancer Res; 1994; 14(3A):953-61. PubMed ID: 8074498
[TBL] [Abstract][Full Text] [Related]
18. Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing.
Rivoltini L; Radrizzani M; Accornero P; Squarcina P; Chiodoni C; Mazzocchi A; Castelli C; Tarsini P; Viggiano V; Belli F; Colombo MP; Parmiani G
J Immunol; 1998 Aug; 161(3):1220-30. PubMed ID: 9686582
[TBL] [Abstract][Full Text] [Related]
19. The Fas death pathway controls coordinated expansions of type 1 CD8 and type 2 CD4 T cells in Trypanosoma cruzi infection.
Guillermo LV; Silva EM; Ribeiro-Gomes FL; De Meis J; Pereira WF; Yagita H; DosReis GA; Lopes MF
J Leukoc Biol; 2007 Apr; 81(4):942-51. PubMed ID: 17261545
[TBL] [Abstract][Full Text] [Related]
20. Evidence for the functional binding in vivo of tumor rejection antigens to antigen-presenting cells in tumor-bearing hosts.
Shimizu J; Zou JP; Ikegame K; Katagiri T; Fujiwara H; Hamaoka T
J Immunol; 1991 Mar; 146(5):1708-14. PubMed ID: 1993850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
